On Thursday, in the course of Afternoon trade, Shares of Coca-Cola Enterprises Inc (NYSE:CCE), dropped -0.93%, and is now trading at $ 43.06.
Coca-Cola Enterprises, will release second-quarter 2015 earnings before the market opens on Thursday, July 30, 2015.
A conference call talk about these results will be webcast live through the company’s website, www.cokecce.com, at 10:00 a.m. EDT, 3:00 p.m. BST, and 4:00 p.m. CEST. A replay of the presentation will be accessible later that day.
Coca-Cola Enterprises, Inc. produces, distributes, and markets non-alcoholic beverages in Belgium, continental France, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, and Sweden.
During an Afternoon trade, Shares of Cerus Corporation (NASDAQ:CERS), dipped -1.98%, and is now trading at $ 4.95.
Cerus Corporation, declared that William “Obi” Greenman, Cerus’ president and chief executive officer, is planned to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 3:00 PM ET on Wednesday, July 8, 2015.
Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, counting viruses, bacteria, and parasites, in addition to potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Shares of Pacific Ethanol Inc (NASDAQ:PEIX), during its Thursday’s current trading session climbed 1.83%, and is now trading at $10.01.
Pacific Ethanol Inc, declared it accomplished its merger with Aventine Renewable Energy Holdings, Inc. (“Aventine”).
Neil Koehler, the company’s president and CEO, stated: “We are happy to complete this transformative acquisition, establishing Pacific Ethanol as the sixth largest producer of ethanol in the United States. In addition to more than doubling our ethanol production capacity, this synergistic transaction expands our geographic footprint, leverages our existing infrastructure to reach new markets and customers and enhances our overall scale and co-product diversification. We look forward to working with the Aventine employees to achieve a smooth integration and accelerate the growth of our combined company.”
Pacific Ethanol, Inc. produces and markets low-carbon renewable fuels in the Western United States. It sells ethanol primarily to gasoline refining and distribution companies. The company also provides ethanol transportation, storage, and delivery services through third-party service providers.
Finally, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), gained 2.58% to $4.40.
Catalyst Pharmaceuticals Inc, declared the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst’s Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
“I am happy to welcome Gary to our team. Gary brings broad experience in leading successful development efforts for medicines across various disease states within both biotech and big pharma. Gary is the perfect fit for Catalyst as our product development programs continue to advance. As we near our NDA submission for Firdapse®, we look forward to Gary’s contributions to expanding the use of Firdapse® for other indications, furthering the development of CPP-115, and potentially expanding our development pipeline to comprise new drugs for other rare diseases.” said Patrick J. McEnany, Chief Executive Officer of Catalyst. He continued “I would also like to thank Chuck Gorodetzky for his noteworthycontributions to Catalyst over the past 10 years and for his commitment to bringing new therapies to people suffering from unmet medical needs.”
Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
